Professor George Hruby
/content/dam/genesiscare/headshots/au-doctor-headshots/AU_Oncology_Headshot_GA_Prof George Hruby.jpg

A/Prof. George Hruby

A/Prof. George Hruby
BHB MBChB, FRANZCR, Radiation Oncologist

Languages spoken




Mater Hospital, Sydney (Oncology)
Mater Hospital, Sydney (Oncology)
-33.83166139694626, 151.20156682718073
Darlinghurst (Oncology)
Darlinghurst (Oncology)

Clinical interests in urological (including prostate) and gastrointestinal (GI) cancers.

Following a fellowship at the Royal Prince Alfred Hospital in 1999, George was awarded a clinical fellowship at the University of Toronto. He spent 13 months in Toronto at a high volume academic centre focused on genito-urinary cancers. In addition to the clinical workload, multi-disciplinary meetings and clinical research; specific goals included exposure to improvements in external beam techniques, such as dose escalation, and in particular training in, being mentored and becoming competent in prostate brachytherapy.

In Dec 2000 he commenced as Staff Specialist in Radiation Oncology at the Royal Prince Alfred Hospital, (now Lifehouse). Specialisations included genito-urinary, and gastro-intestinal malignancies as well as melanoma and merkel cell carcinoma, the latter due to a close association with the melanoma unit. George Hruby was responsible for seeing prostate cancer patients at RPA, Concord and Dubbo, where he flew to an outreach clinic once a month. He has also established a close working relationship with the urologists in Noumea and has treated many New Caledonian men with prostate cancer over the years.

Clinical milestones have included collaborating on the establishment of the High Dose Rate brachytherapy program at Royal Prince Alfred Hospital. This is a multi-disciplinary collaboration involving urology, radiation oncology, medical physics and anaesthetics.

Whilst at RPA, George was actively involved in the introduction of a number of modern radiation techniques for both anal cancer (2009) and prostate cancer (2010). In 2014, prostate cancer patients first started being treated with further innovative technology, in particular for oligo-metastatic disease.

A/Prof Hruby has always been heavily involved in clinical audit and research so that doctors and their patients may better understand the implications of their treatment. George has been heavily involved and recruited many patients to local, national and international trials and is an active participant in TROG and ANZUP.

He has mentored and taught radiation oncology registrars as well as medical students via the University of Sydney medical school. He is an advocate of radiation oncology, and is often called upon to speak at conferences, prostate cancer forums or to teach colleagues. George has presented at many scientific meetings and has co-authored over 75 peer reviewed publications.